- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 3, 2023
Highlights
- Market Cap
- $324.29M
- Enterprise Value
- $262.59M
- EPS (TTM)
- -$1.20
- Gross Profit (TTM)
- -$546.00K
- EBITDA (TTM)
- -$87.35M
- Year Range
- $4.03 - $10.99
- Target Price
- $18.50
- ROA (TTM)
- -34.95%
- ROE (TTM)
- -37.80%
- Avg. Volume (1M)
- 948K
- Avg. Volume Value (1M)
- $4.47M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LXEO Performance Chart
Lexeo Therapeutics Inc. Common Stock (LXEO) is down 58.4% since the beginning of the year. At $4 per share, LXEO is trading 62.4% below its 52-week high of $11.
Loading charts...
Compare this symbol against anything
Returns By Period
Lexeo Therapeutics Inc. Common Stock (LXEO) has returned -58.41% so far this year and -10.41% over the past 12 months.
Lexeo Therapeutics Inc. Common Stock
- 1D
- -5.06%
- 1M
- -11.94%
- 6M
- -44.26%
- YTD
- -58.41%
- 1Y
- -10.41%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -26.21%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
LXEO Monthly Returns History
Based on dividend-adjusted daily data since Nov 3, 2023, LXEO's average daily return is +0.07%, while the average monthly return is +0.11%. At this rate, an investment would double in approximately 52.5 years.
Historically, 42% of months were positive and 58% were negative. The best month was Oct 2025 with a return of +50.8%, while the worst month was Feb 2025 at -47.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, LXEO closed higher 50% of trading days. The best single day was Mar 24, 2025 with a return of +50.9%, while the worst single day was May 6, 2025 at -27.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.38% | -3.10% | -20.06% | -0.78% | -9.75% | -9.44% | -11.28% | -58.41% | |||||
| 2025 | -17.48% | -47.33% | 21.33% | 13.26% | -30.79% | 47.79% | 17.66% | 1.27% | 38.62% | 50.75% | -1.50% | 0.71% | 50.91% |
| 2024 | 27.72% | -14.70% | 7.25% | -20.60% | 33.57% | -3.55% | -21.76% | -8.29% | -21.46% | -12.61% | 4.18% | -20.05% | -50.97% |
| 2023 | 33.89% | 5.50% | 41.26% |
Benchmark Metrics
Lexeo Therapeutics Inc. Common Stock has an annualized alpha of -20.29%, beta of 1.89, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 03, 2023.
- This stock participated in 347.25% of S&P 500 Index downside but only 65.16% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -20.29%
- Beta
- 1.89
- R²
- 0.08
- Upside Capture
- 65.16%
- Downside Capture
- 347.25%
Return for Risk
Risk / Return Rank
LXEO ranks 38 for risk / return — above 38% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Lexeo Therapeutics Inc. Common Stock (LXEO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LXEO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.58 | ||
| Sortino ratioReturn per unit of downside risk | -1.68 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.25 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.21 | 2.00 | -2.21 |
| Martin ratioReturn relative to average drawdown | -0.37 | 8.49 | -8.86 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lexeo Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lexeo Therapeutics Inc. Common Stock was 90.46%, occurring on Apr 7, 2025. The portfolio has not yet recovered.
The current Lexeo Therapeutics Inc. Common Stock drawdown is 77.99%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-90.46%Apr 2025 | 9mo 27d | — | 2y 1moJun 2024 - now | 2025 selloff2025 |
-36.66%Dec 2023 | 5d | 1mo 6d | 1mo 11dDec 2023 - Jan 2024 | — |
-30.47%Apr 2024 | 3mo 2d | 1mo 18d | 4mo 20dJan 2024 - Jun 2024 | — |
-6.14%Jun 2024 | 1d | 2d | 2dJun 2024 - Jun 2024 | — |
-3.88%Nov 2023 | 1d | 6d | 7dNov 2023 - Nov 2023 | — |
Drawdown Indicators
| LXEO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.46% | -56.78% | -33.68% |
Max Drawdown (1Y)Largest decline over 1 year | -61.15% | -9.10% | -52.05% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -77.99% | -1.58% | -76.41% |
Average DrawdownAverage peak-to-trough decline | -51.86% | -10.70% | -41.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.57% | 2.14% | +32.43% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lexeo Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Lexeo Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LXEO in comparison with other companies in the Biotechnology industry. Currently, LXEO has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LXEO
Add Lexeo Therapeutics Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LXEO